Federal Preemption Defense Under Fire In Draft House Bills
This article was originally published in The Gray Sheet
Executive Summary
A one-sentence provision tucked into draft legislation circulating in a House subcommittee seeks to weaken device and drug manufacturers' ability to claim FDA approval as a defense in state product liability lawsuits
You may also be interested in...
Controversy Persists Over House Pre-emption Provision
Device industry support for the House medical device user fee reauthorization bill is threatened by language that companies say would make them more vulnerable to patient lawsuits
Controversy Persists Over House Pre-emption Provision
Device industry support for the House medical device user fee reauthorization bill is threatened by language that companies say would make them more vulnerable to patient lawsuits
Industry Alarmed By Third-Party Audit, Registry Provisions In Draft House Bills
A House subcommittee released nine pieces of draft FDA legislation June 6, including several provisions that mobilized device industry lobbyists to fight for changes